Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 222 participants.
Also called NCT02949193
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 222 participants
- Sponsor
- Registry
-
NCT02949193
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02949193. Randomized; quadruple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2014-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- evogliptin
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Dong-A ST Co., Ltd.
Record details
- Record id
cardio:ct-nct02949193- Content hash
cc658bef6a6659155bba919bc1c95ab2323b92f45dea41eca6f7b664bfe8f83e